trending Market Intelligence /marketintelligence/en/news-insights/trending/hnkielo-wcekodu9q6ctgq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Idera Pharmaceuticals implements 1-for-8 reverse stock split

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Idera Pharmaceuticals implements 1-for-8 reverse stock split

Idera Pharmaceuticals Inc.'s board approved a 1-for-8 reverse split of its stock, effective July 27.

The split-adjusted common shares will trade on the Nasdaq Capital Market starting July 30.

Shareholders of the Cambridge, Mass.-based drug developer previously approved the reverse stock split, which reduced Idera Pharmaceuticals' number of issued and outstanding shares to about 27.2 million, from about 217.4 million.

Computershare Trust Co. NA is acting as exchange agent and transfer agent for the reverse stock split.